Taking Mounjaro with a low BMI: what the evidence and UK licensing actually say

What NICE and the UK licence actually require

NICE's appraisal of tirzepatide (TA1026, published December 2024) recommends the medicine for adults with a BMI of 35 or above alongside at least one weight-related comorbidity for NHS use. The private-prescription licence, set by the Mounjaro SmPC, is somewhat broader (BMI ≥30, or ≥27 with a qualifying condition) but it does not extend below 27 under any routine circumstance. Lower thresholds apply for some ethnic backgrounds under UK guidance, but the reduction is 2.5 kg/m² at most; it does not open the door to use at a genuinely healthy BMI.

The reason for those thresholds is not bureaucratic caution. They reflect where clinical trial evidence exists. SURMOUNT-1, the pivotal phase-three study published in the New England Journal of Medicine, enrolled adults with a BMI of 30 or above (or 27 or above with a comorbidity). Researchers did not study tirzepatide in people with a healthy BMI, so its safety and effect in that group are simply not known from trial data. A prescriber working within the law cannot rely on extrapolation.

If you are close to the threshold and unsure where you stand, the NHS BMI calculator gives a starting-point figure, though a clinical consultation will always consider the fuller picture, including waist measurement and any weight-related conditions you may have.

What the physiological risks look like at a low BMI

Tirzepatide works by signalling to the brain that the body is fed, it slows gastric emptying, blunts appetite and reduces overall calorie intake. Those effects are useful when there is a meaningful amount of excess body fat. At a healthy or low BMI, the same mechanisms become a problem.

The most documented concern is lean muscle loss. On GLP-1 and dual GIP/GLP-1 medicines, weight reduction includes a proportion of lean tissue alongside fat. In people with obesity this is offset by the much larger mass of adipose tissue being lost. At a low BMI, muscle and bone density are proportionally more exposed. Severe nausea and reduced appetite (the most common side effects noted in the NHS medicines information for tirzepatide) compound the problem by making adequate protein and calorie intake genuinely difficult.

Gallbladder issues and dehydration from persistent vomiting are also recognised risks on tirzepatide; both are harder to manage safely when starting body weight is already low. The full picture of how Mounjaro works in the body sets out these mechanisms in more detail. Separately, if there is any history of disordered eating, a prescriber will want to explore that carefully before any appetite-suppressing medicine is considered, regardless of BMI.

Why obtaining Mounjaro outside a legitimate prescription is especially dangerous here

The MHRA has warned repeatedly about counterfeit weight-loss pens sold online, including fake tirzepatide. For someone sourcing the medicine without a prescription and without a clinical consultation, there is no one checking whether the BMI threshold is met, no one reviewing the supply chain, and no one to call when side effects become serious. The medicine itself may not be what the label claims.

A prescriber's refusal to prescribe at a low BMI is not a bureaucratic hurdle, it is the clinical safety net working as intended. If you are considering where to access Mounjaro through a registered UK pharmacy, the first step is always a full clinical consultation, and the outcome of that consultation determines whether any prescription is issued. Paying for a consultation that results in no prescription is, frankly, the system doing its job.

For context on how legitimate private treatment is costed and what a single transparent price includes, the weight-loss treatment overview sets that out plainly.

What to do if you are below the BMI threshold but concerned about your weight

Weight and body composition are not the same thing. Someone can have a BMI in the normal range and still carry metabolically active visceral fat, particularly in certain ethnic backgrounds or after significant muscle loss. If you are concerned, a GP is the right starting point, they can assess waist circumference, blood lipids, blood pressure and other markers that BMI alone misses.

For people who do meet the licensed BMI criteria, a fuller guide to Mounjaro covers what treatment involves from the first consultation onwards, including practical questions such as what to do if you take your injection a day late, whether taking it a day early causes problems, and what the risks are if you use an out-of-date pen. Our clinical team reviews every case; if tirzepatide is not clinically appropriate, the consultation will say so clearly rather than issue a prescription anyway. Speak to our prescribers if you are unsure where you stand, a consultation is free, and honesty about the outcome is part of the service.